0001104659-22-040391.txt : 20220330 0001104659-22-040391.hdr.sgml : 20220330 20220330212654 ACCESSION NUMBER: 0001104659-22-040391 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210913 FILED AS OF DATE: 20220330 DATE AS OF CHANGE: 20220330 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CONTE LISA A CENTRAL INDEX KEY: 0001008377 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 22788804 MAIL ADDRESS: STREET 1: 213 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 4 1 tm2210715-10_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-09-13 0 0001585608 Jaguar Health, Inc. JAGX 0001008377 CONTE LISA A C/O JAGUAR HEALTH, INC. 200 PINE STREET, SUITE 400 SAN FRANCISCO CA 94104 1 1 0 0 CEO and President Common Stock 2021-09-13 4 P 0 7968 2.51 A 8003 D Restricted stock units 2022-03-28 4 A 0 606280 0 A Common Stock 606280 606280 D Restricted stock units 2022-03-28 4 A 0 25000 0 A Common Stock 25000 25000 D On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "Reverse Stock Split). Upon effectiveness of the Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock. Granted pursuant to the issuer's 2014 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice. The restricted stock units vest upon (i) successful completion of the pivotal trial of crofelemer (Mytesi) for cancer-therapy related diarrhea and (ii) successful completion of the investigator-initiated trials in support of the proof-of-concept requirement for early access program for patient access in Europe. /s/ Steven R. King, Attorney-in-Fact 2022-03-30